Related Experiment Videos
Role of interferons in demyelinating disease
1School of Medicine, University of Maryland, Baltimore, USA.
Journal of Neural Transmission. Supplementum
|January 1, 1997
Summary
Interferon beta 1b (Betaseron) was the first FDA-approved treatment to modify multiple sclerosis (MS) progression. This therapy, administered subcutaneously, reduced relapse frequency and white matter lesions.
Area of Science:
- Neuroimmunology
- Pharmacological treatment of Multiple Sclerosis (MS)
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Previous interferon trials in MS laid the groundwork for current therapeutic strategies.
- The need for disease-modifying therapies for MS was significant prior to 1993.
Purpose of the Study:
- To evaluate the efficacy of Interferon beta 1b (Betaseron) in altering the natural history of Multiple Sclerosis (MS).
- To assess the impact of Interferon beta 1b on MS relapse rates and MRI-measured white matter pathology.
Main Methods:
- Subcutaneous injection of Interferon beta 1b (Betaseron) every other day.
- Utilized Magnetic Resonance Imaging (MRI) to measure changes in central white matter pathology.
- Built upon data from twelve prior interferon trials in MS patients.
Main Results:
- Interferon beta 1b (Betaseron) demonstrated a reduction in the frequency of MS relapses.
- The treatment led to a decrease in the expansion of central white matter pathology as observed on MRI.
- Established Interferon beta 1b as the first disease-modifying therapy for MS.
Conclusions:
- Interferon beta 1b (Betaseron) is effective in modifying the course of Multiple Sclerosis (MS).
- The therapeutic effect of beta interferon likely involves the inhibition of gamma interferon.
- Future MS treatment may involve combination therapies with complementary immunologic agents.